Is Dyne Therapeutics, Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Dyne Therapeutics, Inc (DYN) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Dyne Therapeutics, Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Dyne Therapeutics, Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Dyne Therapeutics, Inc?

Muslim investors may consider investing in Dyne Therapeutics, Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Dyne Therapeutics, Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Dyne Therapeutics, Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Dyne Therapeutics, Inc updated?

The Shariah compliance status of Dyne Therapeutics, Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Dyne Therapeutics, Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Dyne Therapeutics, Inc?

You can check the latest Shariah compliance status of Dyne Therapeutics, Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

DYN Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 14, 2026

Report Source: 2026 1st Quarter Report

Analyst's Ratings for Dyne Therapeutics, Inc (DYN)

Based on 20 analysts giving stock ratings to Dyne Therapeutics, Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Dyne Therapeutics, Inc. Stock Analysis DYN

United States Health Care Mid Cap Report: Q1, 2026

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 258 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.

Key Statistics of Dyne Therapeutics, Inc (DYN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$17.19$17.92

Today's Open

$17.85

Volume

1.20M

P/E Ratio (TTM)

52 Week Range

$8.06$25.00

Market Cap

2.89B

Avg. Volume

1.61M

Dividend Yield

Financial Metrics & Statements of Dyne Therapeutics, Inc (DYN)

FAQ's for Dyne Therapeutics, Inc (DYN)

According to Musaffa’s Shariah screening methodology, Dyne Therapeutics, Inc (DYN) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.